Morepen Laboratories Ltd

Morepen Laboratories Ltd share price inched up 4.83% to Rs 132.5 after the company's net profit saw a strong growth of 57.75% to Rs 88.89 crore, while revenue from operations increased sharply by 30.94% to Rs 746.5 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.44 lakh crore, easing 4.06%. It has marginally improved by 3.17% over last one week and edged lower by 0.26% in last one month while the market capitalization of Morepen Laboratories Ltd has increased 14.42% and 134.60% in the same period respectively. Profit before tax (PBT) of Morepen Laboratories Ltd stood at Rs 116.54 crore in Q3 FY26, rallying 155.07% year-on-year, and expanding by 56.37% quarter-on-quarter. EBITDA came in at Rs 114 crore, jumping 339.27% YoY and surging by 47.92% sequentially. Total expenses jumped by 27.73% to Rs 633.46 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 411.91 crore, witnessing a sharp rise of 25.44% YoY, while employee benefits expense was at Rs 79.69 crore, soaring 27.63% YoY. For the TTM ended FY26, revenue from operations declined slightly by 0.33% to Rs 1805.69 crore, while net profit fell 18.95% to Rs 95.65 crore, compared to previous TTM. EBITDA surged by 16216% to Rs 104.31 crore, and PBT plunged by 22.69% to Rs 119.92 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 32.64 crore in FY26, as against Rs 32.06 crore in FY25. Morepen Laboratories Ltd soared by 173.31% in last one year, significantly outperforming the benchmark BSE Sensex which has reduced by 13.19% during the same period.

Morepen Laboratories Limited announced changes in senior management personnel effective October 27, 2026, including Charanjeet Chitakara's promotion from General Manager (Quality Control) to Assistant Vice President (Quality Control) and Vivan Prashar's promotion from Assistant Vice President (Projects & Engineering) - Operations (API) to Vice President (Projects & Engineering) - Operations (API).

Morepen Laboratories Ltd share price inched up 2.56% to Rs 126.4 after the company's net profit surged by 57.75% to Rs 88.89 crore, while revenue from operations gained significantly 30.94% to Rs 746.5 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.54 lakh crore, easing 3.41%. It has marginally improved by 0.07% over last one week and softened by 3.01% in last one month while the market capitalization of Morepen Laboratories Ltd has improved by 3.73% and 118.61% in the same period respectively. Profit before tax (PBT) of Morepen Laboratories Ltd stood at Rs 116.54 crore in Q3 FY26, jumping 155.07% year-on-year, and surging by 56.37% quarter-on-quarter. EBITDA came in at Rs 114 crore, rallying 339.27% YoY and expanding by 47.92% sequentially. Total expenses jumped by 27.73% to Rs 633.46 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 411.91 crore, witnessing a sharp rise of 25.44% YoY, while employee benefits expense was at Rs 79.69 crore, witnessing a strong rise of 27.63% YoY. For the TTM ended FY26, revenue from operations eased 0.33% to Rs 1805.69 crore, while net profit dropped 18.95% to Rs 95.65 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 16216% to Rs 104.31 crore, and PBT collapsed by 22.69% to Rs 119.92 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 32.64 crore in FY26, as against Rs 32.06 crore in FY25. Morepen Laboratories Ltd rallied 160.73% in last one year, significantly outperforming the benchmark BSE Sensex which has reduced by 13.18% during the same period.

Morepen Laboratories Limited announced record revenue and earnings for the quarter and half year ended September 30, 2026, driven by the commercial scale-up of its contract development and manufacturing organization (CDMO) business, with revenue reaching Rs 755 crore. The company's H1 export revenue was Rs 654 crore, up 122% year-over-year, now representing approximately 50% of its sales revenue.

Morepen Laboratories Limited will close its trading window from October 1, 2026, until 48 hours after the announcement of its unaudited consolidated and standalone financial results for the quarter and half year ended September 30, 2026, in accordance with SEBI regulations and the company’s insider trading policy.

Morepen Laboratories Limited announced that its wholly owned subsidiary, Morepen RX Limited (MRX), has allotted 20,00,00,000 equity shares with a face value of Rs 10 each, totaling Rs 20,00,00,000, to the company through a rights issue. Consequently, Morepen Laboratories Limited’s shareholding in MRX has increased to 2,70,82,356 equity shares, and MRX continues to be a wholly owned subsidiary. MRX, incorporated on March 17, 2023, had a turnover of Rs 5,449.84 lakh and a net worth of Rs 47.72 lakh based on audited financial statements for the financial year ended March 31, 2026.

A Monitoring Agency report indicates mixed progress for Morepen Laboratories Limited regarding the utilization of funds raised through an issuance. While the company has largely deployed the Rs 88.83 crore initially planned for completion by March 31, 2025, and the Rs 33.97 crore slated for March 31, 2026, timelines have been extended to March 31, 2026, and March 31, 2027, respectively, raising concerns about project planning and execution. The report notes a Rs 4.55 crore transfer to the company’s current account and a remaining balance of Rs 0.09 crore, prompting a review of vendor billing processes. Despite these delays, the company has effectively utilized funds for working capital and made prudent short-term investments, and the report acknowledges flexibility in fund deployment. The agency recommends strengthening project management, improving internal oversight, and enhancing transparency with investors.

Morepen Laboratories Ltd share price ticked higher by 1.19% to Rs 57.68 after the company's net profit soared by 258.92% to Rs 56.35 crore, while revenue from operations gained 17.62% to Rs 570.13 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.75 lakh crore, rising 5.95%. It has improved by 1.51% over last one week and advanced by 11.59% in last one month while the market capitalization of Morepen Laboratories Ltd has marginally improved by 4.32% and 32.41% in the same period respectively. Profit before tax (PBT) of Morepen Laboratories Ltd stood at Rs 74.53 crore in Q2 FY26, jumping 380.22% year-on-year, and surging by 220.01% quarter-on-quarter. EBITDA came in at Rs 77 crore, rallying 291.30% YoY and expanding by 383.80% sequentially. Total expenses inched up 6.42% to Rs 495.94 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 328.38 crore, increasing 13.01% YoY, while employee benefits expense was at Rs 62.44 crore, easing 6.26% YoY. For the TTM ended FY26, revenue from operations posted a slight growth of 7.17% to Rs 1811.58 crore, while net profit saw a strong growth of 22.15% to Rs 118.02 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 13917% to Rs 155.71 crore, and PBT registered a growth of 14.54% to Rs 155.11 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 32.06 crore in FY26, as against Rs 73.37 crore in FY25. Morepen Laboratories Ltd slipped 0.14% in last one year, outperforming the benchmark BSE Sensex which has softened by 2.94% during the same period.

Morepen Laboratories Limited announced its highest-ever quarterly revenue of Rs 575.31 crore and earnings for the quarter ended June 30, 2026, alongside a 207% increase in EBITDA and a 394% rise in profit after tax. The company’s CDMO mandate, valued at Rs 825 crore, has entered full-scale commercialization, with Rs 58 crore in commercial dispatches completed during the quarter, supported by a 31% growth in the API business and 19% growth in the medical devices business.

Morepen Laboratories will hold a meeting of the Board of Directors of the Company on 4 August 2026.